Your browser doesn't support javascript.
loading
A novel assessment method for COVID-19 humoral immunity duration using serial measurements in naturally infected and vaccinated subjects.
de Boer, Jasper; Saade, Ursula; Granjon, Elodie; Trouillet-Assant, Sophie; Saade, Carla; Pottel, Hans; Zrein, Maan.
Afiliação
  • de Boer J; Department of Public Health and Primary Care, KU Leuven Campus Kulak, Kortrijk, Belgium.
  • Saade U; R&D Department, InfYnity Biomarkers, Lyon, France.
  • Granjon E; R&D Department, InfYnity Biomarkers, Lyon, France.
  • Trouillet-Assant S; Virology Laboratory, Institute of Infectious Agents, Laboratory associated with the National Reference Centre for Respiratory Viruses, Civils Hospices of Lyon, Lyon, France.
  • Saade C; International Center of Research in Infectiology, Institut National de la Santé et de la Recherche Médicale U1111, Centre National de la Recherche Scientifique UMR5308, Ecole Normale Supérieure de Lyon, Claude Bernard Lyon 1 University, Lyon, France.
  • Pottel H; Virology Laboratory, Institute of Infectious Agents, Laboratory associated with the National Reference Centre for Respiratory Viruses, Civils Hospices of Lyon, Lyon, France.
  • Zrein M; Department of Public Health and Primary Care, KU Leuven Campus Kulak, Kortrijk, Belgium.
PLoS One ; 17(9): e0274553, 2022.
Article em En | MEDLINE | ID: mdl-36173972
BACKGROUND: Collecting information on sustainability of immune responses after infection or vaccination is crucial to inform medical decision-making and vaccination strategies. Data on how long-lasting antibodies against SARS-COV-2 could provide a humoral and protective immunity and prevent reinfection with SARS-CoV-2 or its variants is particularly valuable. This study presents a novel method to quantitatively measure and monitor the diversity of SARS-CoV-2 specific antibody profiles over time. METHODS: Serum samples from two groups were used in this study: Samples from 20 naturally infected subjects (followed for up to 1 year) and samples from 83 subjects vaccinated with one or two doses of the Pfizer BioNtech vaccine (BNT162b2/BNT162b2) (followed for up to 6 months). The Multi-SARS-CoV-2 assay, a multiparameter serology test developed for the serological confirmation of past-infections, was used to determine the reactivity of six different SARS-CoV-2 antigens. For each subject sample, 3 dilutions (1/50, 1/400 and 1/3200) were defined as an optimal set over the six antigens and their respective linear ranges. This allowed accurate quantification of the corresponding six antibodies. Nonlinear mixed-effects modelling was applied to convert intensity readings from 3 determined dilutions to a single quantification value for each antibody. RESULTS: Median half-life for the 20 naturally infected vs 74 vaccinated subjects (two doses) was 120 vs 50 days for RBD, 127 vs 53 days for S1 and 187 vs 86 days for S2 antibodies respectively. CONCLUSION: The newly proposed method, based on a series of a limited number of dilutions, can convert a conventional qualitative assay into a quantitative assay. This conversion helps define the sustainability of specific immune responses against each relevant viral antigen and can help in defining the protection characteristics after an infection or a vaccination.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Imunidade Humoral / COVID-19 Tipo de estudo: Prognostic_studies / Qualitative_research Limite: Humans Idioma: En Revista: PLoS One Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Imunidade Humoral / COVID-19 Tipo de estudo: Prognostic_studies / Qualitative_research Limite: Humans Idioma: En Revista: PLoS One Ano de publicação: 2022 Tipo de documento: Article